Generic Name and Formulations:
Methenamine 81mg, sodium biphosphate 40.8mg, phenyl salicylate 32.4mg, methylene blue 10.8mg, hyoscyamine sulfate 0.12mg; tabs.
Indications for URELLE:
Treatment of symptoms of irritative voiding. Relief of local symptoms due to lower UTIs or diagnostic procedures.
1 tab 4 times daily.
≤6yrs: not recommended. >6yrs: individualize dose.
Cardiac disease. GI or GU obstruction. Glaucoma. Myasthenia gravis.
Maintain acid urine and adequate hydration. Gastric ulcers. Discolors urine/feces. Discontinue if rapid pulse, dizziness, or blurred vision occurs. Elderly. Pregnancy (Cat.C). Nursing mothers.
Urinary tract analgesic/antispasmodic/antiseptic.
Allow at least 2 hours after ketoconazole. May be potentiated by antimuscarinics, antimyasthenics, MAOIs, opioids. May be antagonized by thiazide diuretics, urinary alkalinizers. Separate dosing of antacids, antidiarrheals by 1 hour. May reduce absorption of other drugs. Sulfonamides precipitate with formaldehyde in urine; avoid concomitant use.
Rapid pulse, flushing, blurred vision, dizziness, shortness of breath, acute urinary retention, difficult micturition, dry mouth, nausea, vomiting.
Clinical Pain Advisor Articles
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Tools to Address the Opioid Crisis
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- Patterns of Non-Medical Prescription Opioid Use in Adolescents
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- FDA Panel Votes in Favor of Abuse-Deterrent Oxycodone Reformulation
- FDA Proposes New Restrictions on Sale of Electronic Nicotine Delivery Systems
- Central Sensitization in Greater Trochanteric Pain Syndrome
- Pain Acceptance May Reduce Headache-Related Disability in Migraine
- FDA Issues Safety Alert Regarding Intrathecal Delivery of Pain Meds